Filing Flows › Longeveron (LGVN) › Recalls, complaints & regulation
Longeveron (LGVN): clinical trials
Longeveron (LGVN) beyond its filings: 1 active clinical trial.
Longeveron's latest quarter
Longeveron, Q2 2026: revenue $287K (-9% year over year), net loss $6.1M, operating cash flow −$5.7M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Longeveron have?
1 active study on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.